Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-07-09
2010-02-16
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C435S006120, C435S325000, C435S375000
Reexamination Certificate
active
07662951
ABSTRACT:
The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against beta-secretase (BACE), amyloid precursor protein (APP), pin-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1 and/or PS-2 expression or activity.
REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 2003/0083294 (2003-05-01), Sullenger et al.
patent: 2003/0143708 (2003-07-01), Blatt et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2359180 (2000-03-01), None
patent: WO-90/14090 (1990-11-01), None
patent: WO-94/01550 (1994-01-01), None
patent: WO-99/32619 (1999-07-01), None
patent: WO-99/49029 (1999-09-01), None
patent: WO-00/44895 (2000-08-01), None
patent: WO-00/44914 (2000-08-01), None
patent: WO-01/36646 (2001-05-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-02/22636 (2002-03-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-03/064626 (2003-08-01), None
patent: WO-03/064626 (2003-08-01), None
Caplen NJ. RNAi as a Gene Therapy Approach. Expert Opinon. Biol. Thera. (2003) vol. 3(4) 575-586. Ashley Publications Ltd.
Parrish et al. Functional Anatomy of a dsRNA trigger: differential requirements for the two trigger strands in RNA interference. Molecular Cell, 2000, vol. 6: 1077-1087. Cell Press.
Braasch et al. Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression. Biochemistry 2002, Vo. 41(14): 4503-4510.
Pieken et al. Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes. Science, 1991, vol. 253: pp. 314-317.
Vassar et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by transmemebrane aspartic protease BACE. Science Oct. 1999, vol. 286: pp. 735-714.
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,”Oligonucleotides13(5):303-312 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,”Methods26(2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,”EMBO J.20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes Dev.15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against Bcl-2,”Nucleic Acids Research Supplement2:251-252 (2002).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,”Biochemical and Biophysical Research Communications295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,”Biochemical and Biophysical Research Communications281:639-644 (2001).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,”Molecular Interventions295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,”Genes and Development13(24):3191-3197 (1999).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Beigelman Leonid
McSwiggen James
Chong Kimberly
Sirna Therapeutics, Inc.
Stracker Elaine C.
LandOfFree
RNA interference mediated treatment of Alzheimer's disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA interference mediated treatment of Alzheimer's disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated treatment of Alzheimer's disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154258